Caxton Advantage Life Sciences Fund

CAXTON ADVANTAGELIFE SCIENCES FUND

HOME

ABOUT US

TEAM

PORTFOLIO

NEWS

CONTACT US

HOMELATEST NEWSAugust 4, 2010Gemin X Closes $8 Million Series E FinancingJune 30, 2010Sunesis Closes $28.5 Million Final Tranche of 2009 Private PlacementJune 7, 2010Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial in Relapsed or Refractory PatientsApril 20, 2010Gemin X Announces $16 Million Series D FinancingMarch 26, 2010VIVUS Announces Date of FDA Advisory Committee Review of Qnexa(R) for the Treatment of ObesityMarch 15, 2010Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010March 4, 2010Anthera Pharmaceuticals Completes Initial Public OfferingExperienceINSIGHTDisciplineClick here for more newsABOUT USExperienceABOUT CAXTON ADVANTAGEExperienced team has developed a targeted late-stage investment strategy that focuses on de-risked opportunities with substantial upsideCaxton Advantage Life Sciences Fund is a leading life sciences investment firm focused on late-stage private and public drug development companies. The Fund’s targeted late-stage investment strategy – in conjunction with the team’s experience, insight, and disciplined approach – has produced successful results for both its investors and portfolio companies. The Fund was established in 2006 by Managing Partners, Eric W. Roberts and A. Rachel Leheny, Ph.D. – one of Wall Street’s premier life sciences investment banking and research teams – along with affiliates of Caxton Associates, a New York-based trading and investment firm. Eric and Rachel have worked together since 1998. The Caxton Advantage investment professionals also include Jay Cecil and Scott Morenstein. Together the team has a collective 75 years of experience and has worked on over 200 financing and M&A transactions in the life sciences industry.InsightInsight on what drives success is key to assessing management and their clinical planDisciplineDisciplined, successful approach has established Caxton Advantage's reputation as a preferred investor for late-stage private and micro-cap public companiesTEAMA. Rachel Leheny, Ph.D.Managing DirectorA. Rachel LehenyA. RACHEL LEHENY, Ph.D.Managing DirectorIn 2004, Dr. Leheny co-founded Caxton Advantage. Dr. Leheny has 25 years of experience in the life sciences industry. From April 2000 to May of 2002, Dr. Leheny was the Head of the Biotechnology Research Team and a Senior Vice President at Lehman Brothers. Dr. Leheny headed the Biotechnology Research Team at UBS Warburg and worked at Hambrecht & Quist, most recently as a Managing Director and Senior Biotechnology Analyst. Dr. Leheny was named a Wall Street Journal research All-Star for stock picking in 1996, 1998, and 2002. Dr. Leheny obtained her A.B. in Chemistry with honors from Harvard College and a Ph.D. in chemistry from Columbia University. She did post-doctoral work at the University of California, Berkeley where she was an NIH fellow and a lecturer. Dr. Leheny currently serves as a Director on the Board of Anthera Pharmaceuticals, was a Board Observer at Corthera and is a Director of the Clearity Foundation, a non-profit organization that provides molecular profiling for women with ovarian cancer. Eric W. RobertsERIC W. ROBERTSManaging DirectorIn 2004, Mr. Roberts co-founded Caxton Advantage. Mr. Roberts has 24 years of experience in the life sciences industry. Most recently, he was Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers. He also served as a member of the Investment Banking Management Committee and as a member of the screening committee for the Lehman Brothers Healthcare Venture Capital Fund. Mr. Roberts was also a Managing Director, Partner and founder of the Life Sciences Department at Dillon, Read & Co. Inc. which was ultimately merged into UBS. At UBS, Mr. Roberts ran the Life Sciences investment banking team. In addition, Mr. Roberts worked at Citicorp in the Citicorp Venture Capital (CVC) group before Dillon Read. Mr. Roberts received a B.S. in Economics from the Wharton School of the University of Pennsylvania. Mr. Roberts currently serves as a Director on the Board of Gemin X Pharmaceuticals and is a Board Observer for Regado Biosciences. Scott MorenstienSCOTT MORENSTEINPrincipalScott Morenstein joined Caxton Advantage in 2007. Scott has 12 years of experience in the life sciences industry. Prior to joining Caxton Advantage, Scott was an investment banker and founding member of Seaview Securities, a boutique investment bank focused on life sciences mergers and acquisitions and private placements. Previously, Scott was also a healthcare investment banker and equity research analyst covering the biotechnology sector at Lehman Brothers. Scott is actively involved in the fund’s investments in Gemin X Pharmaceuticals and Sunesis Pharmaceuticals. Scott currently serves as a Director on the Board of Gemin X Pharmaceuticals. Scott received an MBA from Harvard Business School and a BA from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems. Jay CecilJAY CECILPrincipalJay Cecil joined Caxton Advantage in 2006. Jay has 14 years of experience in the life sciences industry. Prior to joining the Fund, he was a Vice President in the Life Sciences Investment Banking Group at Piper Jaffray. Before Piper Jaffray, Jay worked within the Health Care Investment Banking Group at Montgomery Securities. During his years in life sciences banking, Jay completed over 60 financing and acquisition transactions worth over $5.6 billion for a range of life science clients including Anesta, MGI Pharma, Biomarin Pharmaceuticals, Alexion Pharmaceuticals and ILEX Oncology. Since joining the fund, Jay has played an active role in a number of new investments, including VIVUS, Corthera, Regado Biosciences and Anthera Pharmaceuticals. Jay earned an MBA from The Wharton School, University of Pennsylvania and an MS in Biotechnology from the University of Pennsylvania with a concentration in Immunology. He graduated Phi Beta Kappa from Lehigh University with a degree in Economics.Eric W. RobertsManaging DirectorJay CecilPrincipalScott MorensteinPrincipalPORTFOLIOAnthera PharmaceuticalsantheraA public cardiovascular and inflammatory disease companywww.anthera.comcortheraAcquired by NovartisA private company developing the hormone, Relaxin, in acute heart failurewww.corthera.comgeminxA private company focused on cancer therapeuticswww.geminx.comgentiumA public Italian company treating vascular complications of cancer treatmentwww.gentium.itregadoA private company focused on use of aptamers for reversible treatments in acute care cardiovascular marketswww.regadobiosciences.comsunesisA public company focused on cancer therapeuticswww.sunesis.comvivusA public company primarily focused on treatments for obesity and diabeteswww.vivus.comNASDAQ: ANTHCortheraAcquired by NovartisGemin X PharmaceuticalsGentiumNASDAQ: GENTRegado BiosciencesSunesisNASDAQ: SNSSVivusNASDAQ: VVUSNEWS20102010PORTFOLIO NEWS - 2010August 4, 2010Gemin X Closes $8 Million Series E FinancingJune 30, 2010Sunesis Closes $28.5 Million Final Tranche of 2009 Private PlacementJune 7, 2010Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial in Relapsed or Refractory PatientsApril 20, 2010Gemin X Announces $16 Million Series D FinancingMarch 26, 2010VIVUS Announces Date of FDA Advisory Committee Review of Qnexa(R) for the Treatment of ObesityMarch 15, 2010Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010March 4, 2010Anthera Pharmaceuticals Completes Initial Public OfferingMarch 1, 2010Gentium Announces Management Changes and Corporate RestructuringJanuary 11, 2010Gentium Announces Extension of License and Supply and Cost Sharing Agreements with Sigma-TauJanuary 11, 2010VIVUS Announces Additional Results of Phase 3 avanafil Study in Erectile Dysfunction Showing Efficacy in 15 MinutesJanuary 7, 2010VIVUS Announces Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnea2009PORTFOLIO NEWS - 2009December 23, 2009Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failureDecember 17, 2009Regado Biosciences, Inc. Completes $40 Million Series D FinancingDecember 7, 2009Sunesis Presents Positive Phase 2 Clinical Data of Voreloxin in Acute Myeloid Leukemia at the American Society of Hematology 2009 Annual MeetingDecember 7, 2009Gentium Announces Final Clinical Trial Results for Defibrotide Presented at the American Society of Hematology ConferenceNovember 18, 2009VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect ProfileSeptember 9, 2009Regado Biosciences Announces First Patient Enrolled in Radar (Phase 2b) Study of Reg1 Anticoagulation SystemSeptember 9, 2009VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-MorbiditiesAugust 31, 2009Regado Biosciences Releases Positive Phase 2A Data For The Reversible Anticoagulant System REG1 At The European Society Of Cardiology Congress In Barcelona, SpainAugust 24, 2009Regado Biosciences Announces First Patient Enrolled in Phase 1 Study of Subcutaneously Administered REG1 Anticoagulation SystemAugust 19, 2009Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive DiseaseMay 28, 2009Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009May 30, 2009Gemin X Announces Positive Results in Small Cell Lung Cancer from Phase 1b Trial of Obatoclax at Annual Meeting of the American Society of Clinical OncologyMay 6, 2009Anthera's Varespladib Meets Primary Endpoint In Phase 2 Francis Trial For The Treatment Of Acute Coronary SyndromeApril 1, 2009Sunesis Pharmaceuticals Announces Up To $43.5 Million FinancingMarch 24, 2009Following Encouraging Results Anthera To Continue Impacts Trial For The Prevention Of Acute Chest Syndrome In Patients With Sickle Cell DiseaseMarch 3, 2009Gemin X Initiates Phase 2 Clinical Study of Obatoclax in Combination with Standard Chemotherapy for First-Line Treatment of Small Cell Lung CancerJanuary 15, 2009Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer2008PORTFOLIO NEWS - 2008November 10, 2008Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart FailureAugust 13, 2008Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as ChairmanAugust 6, 2008VIVUS Announces Closing of $65 Million Registered Direct Offering of Common StockAugust 4, 2008David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO2007PORTFOLIO NEWS - 2007December 20, 2007Corthera Closes $23 Million Financing RoundMarch 27, 2007Regado Biosciences Completes $23 Millions Series C Financing 2006PORTFOLIO NEWS - 2006November 20, 2006VIVUS to Raise $33.6 Million in Registered Direct Offering of Common Stock2009200820072006CONTACT USFor more information regarding Caxton Advantage, please contact us at info_caxtonadvantage.com.OFFICE LOCATIONSNew York500 Park AvenueNew York, NY 10022+1 (212) 891-1100 office+1 (212) 692-6072 faxSan Diego12481 High Bluff DriveSuite 150San Diego, CA 92130
Click here for directions
Click here for directionsDisclaimerExperienceLEGAL DISCLAIMERThe material on this website was prepared exclusively for information and discussion purposes, and is not meant to be, nor shall it be construed as, an attempt to define all terms and conditions of any transaction or to contain all information that is, or may be, material to an investor. Neither Caxton Associates LP (“Caxton”) nor Caxton Advantage Venture Partners, L.P. ("CAVP") nor their respective principals or affiliates are soliciting any action based upon this material, and this material is not meant to be, nor shall-it be construed as, an offer or solicitation of an offer for the purchase or sale of any security or advisory or other service. If, in the future, any security or service is offered or sold, such offer or sale shall occur only pursuant to, and a decision to invest therein should be made solely on the basis of, a definitive offering circular, and shall be made exclusively to qualified investors in a private offering exempt from registration under all applicable securities and other laws. Any such offering circular shall contain material information not contained herein, and shall supplement, amend, and/or supersede in its entirety the information referred to herein. All information contained herein is subject to change without notice. Legal DisclaimerCopyright © 2010 Caxton Advantage Life Sciences Fund, L.P.